Compound |
Class |
Targets |
Status/Use |
References |
|
|
|
|
|
AC133,
(anti-CD133-1);
AC141
(anti-CD133-2) |
Mouse IgG1 mAb |
Poorly characterized glycosylated CD133 extracellular epitopes of uncertain specificity;
colon CSCs |
Experimental research,
in vitro detection of CD133+ cells |
[183]
[185]
[189] |
32AT1672
(anti-CD133);
C24B9
(anti-CD133) |
Mouse IgG1 mAb;
rabbit IgG mAb |
Unmodified (non-glycosylated) extracellular epitopes of CD133 |
Experimental research,
in vitro detection of CD133+ glioblastoma cells |
[185]
[187] |
3F8
(anti-GD2) |
Mouse IgG3 mAb |
Human neuroblastoma and osteosarcoma samples and melanoma cell lines;
patients with advanced neuroblastoma and melanoma |
Phase I and II clinical studies in patients with neuroblastoma and melanoma |
[195]
[196]
[197] |
Hu3F8
(anti-GD2) |
Humanized IgG1 and IgG4 mAbs |
Human neuroblastoma cells, neuroblastoma xenograft mice;
patients with neuroblastoma |
Phase I clinical study in patients with high risk neuroblastoma and GD2-positive tumors |
[198]
[199] |
3F8BiAb
(anti-GD2/anti-CD3) |
Heteroconjugate of 3F8 and mouse IgG2a mAb OKT3 |
Human neuroblastoma cell lines |
Experimental research,
in vitro killing of neuroblastoma cells by redirected activated T cells |
[200] |
Ch14.18
(anti-GD2) |
Chimeric mAb:
Fab of mouse anti-GD2 IgG2a mAb 14G2, fused with human Fc constant IgG1 regions |
Patients with melanoma and high-risk neuroblastoma |
Phase I clinical studies in patients with neuroblastoma and melanoma;
phase III clinical studies, combination with cytokines and cytostatic drugs in neuroblastoma patients
|
[202]
[206]
[203]
[204]
[208]
[205] |
TRBs07, Ektomun, Ektomab
(anti-GD2 and anti-GD3/
anti-CD3/Fcγ) |
Triomab; recombinant chimeric two half antibody, each with one light and one heavy chain from mouse IgG2a (Me361) and rat IgG2b (26II6) isotypes. Bispecific, trifunctional mAb construct |
Human melanoma cell lines;
mouse melanoma model treated with Triomab Surek (anti-mouse-CD3/anti-GD2, anti-GD3/Fcγ) |
Experimental research,
in vitro killing of melanoma cells by redirected activated T cells;
induction of tumor eradication and tumor immunity in a mouse melanoma model by Surek |
[209]
[137]
[138] |
KM4056
(anti-Lgr5) |
Rat IgG2b mAb |
CHO cells expressing the human CSC-marker Lgr5 |
Preclinical, xenograft mice |
[217] |
1D9, 4D11, 9G5
(anti-Lgr5) |
Rat IgG mAbs |
Colon CSCs isolated and enriched from patient-derived colorectal cancers |
Preclinical,
In vitro, xenograft mice,
identification of colon CSCs |
[218]
[219] |
